# Teleflex Inc.

**TFX**

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000096943

**D**

**fourth fifth of 369 graded peers in healthcare**

rank 276 of 369; percentile 74.7; sampling error 2.5 points; lower is stronger

A B C D E

**D, the sloth**



## Scoreboard

| | |
|---|---|
| **Profitability** | C<br>percentile 49.6 |
| **Solvency** | C/D<br>percentile 60.9 |
| **Growth and financing** | C/D<br>percentile 60.4 |
| **Reliability** | 0.94 AUC<br>filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025 |
| **Peer failure rate** | 0.52% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | over $2.67B assets<br>total assets $6.9B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress |
| **Inputs computable** | 10 of 14 |
| **Graded from** | filings received through Feb 27, 2026<br>256 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026 |
| **Last close** | $154.77<br>2026-11-09; market equity $6.1B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 27, 2026*

Teleflex Incorporated is referred to herein as "we," "us," "our," "Teleflex" and the "Company." Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products to hospitals and healthcare providers worldwide through a combination of our direct sales force and distributors.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 49.6** | | | | | | |
| Gross profitability | 16.1% | 32.3% | | 69.8 | 365 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (14.3%) | (6.6%) | 31.4 | 800 | 2025-12-31 |
| Gross margin stability, five years | 2.7 pts | 2.8 pts | 47.7 | 242 | 2025-12-31 |
| **Solvency, sleeve percentile 60.9** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | 3.56 | (0.35) | 23.3 | 745 | 2025-12-31 |
| Net debt to EBITDA | 12.97x | 1.82x | 97.3 | 75 | 2025-12-31 |
| Interest coverage | not computable | (4.51x) | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | |
| Current ratio | 2.54x | 2.95x | 62.2 | 826 | 2025-12-31 |
| **Growth and financing, sleeve percentile 60.4** | | | | | |
| Revenue growth, three-year compound | (10.6%) | 10.1% | 85.9 | 411 | 2025-12-31 |
| Free cash flow growth, three-year compound | (82.4%) | 11.0% | 100.0 | 95 | 2025-12-31 |
| Reinvestment rate | not computable | 37.1% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | 0.09% | 2.2% | 51.7 | 694 | 2025-12-31 |
| Net share issuance, one year | (4.7%) | 2.5% | 4.1 | 629 | 2026-02-25 |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 271 | Viatris Inc. (VTRS) | 73.4 | D | |
| 272 | Ovid Therapeutics Inc. (OVID) | 73.6 | D | dilution, short runway |
| 273 | Precision Optics Corporation, Inc. (POCI) | 73.9 | D | dilution, fortress balance sheet |
| 274 | Retractable Technologies Inc. (RVP) | 74.2 | D | fortress balance sheet |
| 275 | NutriBand Inc. (NTRB) | 74.5 | D | fortress balance sheet |
| 276 | Teleflex Inc. (TFX) | 74.7 | D | |
| 277 | Abeona Therapeutics Inc. (ABEO) | 75.0 | D | fortress balance sheet |
| 278 | Standard Biotools Inc. (LAB) | 75.3 | D | late filer, fortress balance sheet |
| 279 | X4 Pharmaceuticals, Inc. (XFOR) | 75.5 | D | dilution, fortress balance sheet |
| 280 | Vir Biotechnology, Inc. (VIR) | 75.8 | D | |
| 281 | Cytosorbents Corp. (CTSO) | 76.1 | D | short runway, fortress balance sheet |

## What the price implies

*at the 2026-11-09 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 1.6% | (1.9%) | 53 |
| Distance from 52-week high | 0.0% | (27.5%) | 90 |
| EBIT to enterprise value | 1.6% | (1.5%) | 60 |
| Free cash flow yield | 0.02% | (1.0%) | 55 |
| Book value to price | 0.57 | 0.27 | 74 |
| Sales to price | 0.32 | 0.29 | 52 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Composite equity issuance, five years | (20.3%) | 20.8% | 9 |
| Relative strength against the sector, log excess return | (0.15) | (0.19) | 53 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score 5 of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | pass |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | pass |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $430.5M |
| Operating cash flow, four quarters | $321.2M |
| Months of runway | not finite |
| Days since last periodic filing | 5 (10-Q received Nov 5, 2026) |
| Median daily dollar volume, 63 sessions | $95.3M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $1.1B | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 2 | assets | us-gaap:Assets | $6.9B | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | $118.4M | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | $24.6M | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$34.0M | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 6 | total debt | us-gaap:LongTermDebt | $2.6B | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 7 | book equity | us-gaap:StockholdersEquity | $3.1B | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $378.6M | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 9 | total debt | us-gaap:LongTermDebt | $1.7B | 2024-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 10 | book equity | us-gaap:StockholdersEquity | $4.3B | 2024-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 11 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $247.9M | 2024-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 12 | net income | us-gaap:NetIncomeLoss | -$905.6M | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivitiesC... | $96.7M | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 14 | assets | us-gaap:Assets | $7.1B | 2024-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 15 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $2.0B | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 16 | gross profit | us-gaap:GrossProfit | $1.0B | 2024-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 17 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.7B | 2024-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 18 | gross profit | us-gaap:GrossProfit | $1.0B | 2023-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 19 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $1.7B | 2023-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 20 | gross profit | us-gaap:GrossProfit | $1.5B | 2022-12-31 | 2025-02-28 | 10-K | 25-000031 |
| 21 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $2.8B | 2022-12-31 | 2025-02-28 | 10-K | 25-000031 |
| 22 | gross profit | us-gaap:GrossProfit | $1.5B | 2021-12-31 | 2024-02-23 | 10-K | 24-000036 |
| 23 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $2.8B | 2021-12-31 | 2024-02-23 | 10-K | 24-000036 |
| 24 | current assets | us-gaap:AssetsCurrent | $1.9B | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 25 | current liabilities | us-gaap:LiabilitiesCurrent | $762.0M | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 26 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | $3.1B | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 27 | liabilities | us-gaap:Liabilities | $3.8B | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 28 | depreciation amortization | us-gaap:Depreciation | $56.1M | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 29 | operating income | us-gaap:OperatingIncomeLoss | $258.7M | 2023-12-31 | 2026-02-27 | 10-K | 26-000019 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| 30 | interest expense | us-gaap:InterestExpense | $85.1M | 2023-12-31 | 2024-02-23 | 10-K | 24-000036 |
| 31 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $95.2M | 2025-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 32 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivitiesC... | $301.9M | 2024-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 33 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $90.4M | 2024-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 34 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivitiesC... | $206.1M | 2023-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 35 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $46.4M | 2023-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 36 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivitiesC... | $342.8M | 2022-12-31 | 2025-02-28 | 10-K | 25-000031 |
| 37 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $79.2M | 2022-12-31 | 2025-02-28 | 10-K | 25-000031 |
| 38 | current assets | us-gaap:AssetsCurrent | $1.5B | 2024-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 39 | current liabilities | us-gaap:LiabilitiesCurrent | $649.4M | 2024-12-31 | 2026-02-27 | 10-K | 26-000019 |
| 40 | assets | us-gaap:Assets | $7.5B | 2023-12-31 | 2025-02-28 | 10-K | 25-000031 |
| 41 | assets | us-gaap:Assets | $6.9B | 2022-12-31 | 2024-02-23 | 10-K | 24-000036 |
| 42 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 44,200,562 | 2026-02-25 | 2026-02-27 | 10-K | 26-000019 |
| 43 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 46,366,463 | 2025-02-25 | 2025-02-28 | 10-K | 25-000031 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.